Please ensure Javascript is enabled for purposes of website accessibility

Novavax Awarded $1.6 Billion From Operation Warp Speed to Fund COVID-19 Vaccine Program

By Keith Speights - Jul 7, 2020 at 10:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The funds will support the rapid development and mass production of the biotech's coronavirus vaccine candidate, NVX-CoV2373.

Novavax (NVAX 2.80%) announced on Tuesday that it has been awarded $1.6 billion by Operation Warp Speed, the program established by the U.S. government to support the rapid development and production of COVID-19 vaccines.

The federal funds will help Novavax complete late-stage development of its COVID-19 vaccine candidate, NVX-CoV2373. Novavax will also use the money to ramp up large-scale manufacturing of NVX-CoV2373 with the goal of delivering 100 million doses of it, potentially before the end of 2020.

Novavax scientist holding instrument

Image source: Novavax. 

NVX-CoV2373 wasn't one of the initial five COVID-19 vaccine candidates selected by Operation Warp Speed last month. However, Health and Human Services Secretary Alex Azar stated, "Adding Novavax' candidate to Operation Warp Speed's diverse portfolio of vaccines increases the odds that we will have a safe, effective vaccine as soon as the end of this year." 

The company began a phase 1/2 clinical study of NVX-CoV2373 in May. Preliminary results from the first phase of this study are expected later this month. Novavax plans to start the phase 2 portion of the trial soon afterward. If all goes well, the biotech hopes to initiate a phase 3 clinical study with up to 30,000 participants in the fall.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$41.47 (2.80%) $1.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.